Christopher E Jensen1, Sanah N Vohra2, Kirsten A Nyrop3, Allison M Deal4, Hyman B Muss5, Eben I Lichtman6, Samuel M Rubinstein7, William A Wood8, Nicholas J Mangieri9, Lee Jamison10, Shakira J Grant11, Sascha A Tuchman12. 1. Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, 170 Manning Drive, Houpt Building, CB# 7305, Chapel Hill, NC 27599, USA; Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, 170 Manning Drive, Houpt Building, CB# 7305, Chapel Hill, NC 27599, USA. Electronic address: christopher.jensen@unchealth.unc.edu. 2. Department of Epidemiology, University of North Carolina at Chapel Hill, 135 Dauer Drive, 2101 McGavran-Greenberg Hall, CB# 7435, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 450 West Drive, Chapel Hill, NC 27599, USA. Electronic address: vohrasn@email.unc.edu. 3. Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, 170 Manning Drive, Houpt Building, CB# 7305, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 450 West Drive, Chapel Hill, NC 27599, USA. Electronic address: kirsten_nyrop@med.unc.edu. 4. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 450 West Drive, Chapel Hill, NC 27599, USA. Electronic address: allison_deal@med.unc.edu. 5. Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, 170 Manning Drive, Houpt Building, CB# 7305, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 450 West Drive, Chapel Hill, NC 27599, USA. Electronic address: hyman_muss@med.unc.edu. 6. Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, 170 Manning Drive, Houpt Building, CB# 7305, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 450 West Drive, Chapel Hill, NC 27599, USA. Electronic address: eben_lichtman@med.unc.edu. 7. Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, 170 Manning Drive, Houpt Building, CB# 7305, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 450 West Drive, Chapel Hill, NC 27599, USA. Electronic address: samuel_rubinstein@med.unc.edu. 8. Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, 170 Manning Drive, Houpt Building, CB# 7305, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 450 West Drive, Chapel Hill, NC 27599, USA. Electronic address: william_wood@med.unc.edu. 9. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 450 West Drive, Chapel Hill, NC 27599, USA. Electronic address: nicholas_mangieri@med.unc.edu. 10. Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, 170 Manning Drive, Houpt Building, CB# 7305, Chapel Hill, NC 27599, USA; Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, 170 Manning Drive, Houpt Building, CB# 7305, Chapel Hill, NC 27599, USA. Electronic address: lee.jamison@unchealth.unc.edu. 11. Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, 170 Manning Drive, Houpt Building, CB# 7305, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 450 West Drive, Chapel Hill, NC 27599, USA. Electronic address: shakira_grant@med.unc.edu. 12. Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, 170 Manning Drive, Houpt Building, CB# 7305, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 450 West Drive, Chapel Hill, NC 27599, USA. Electronic address: sascha_tuchman@med.unc.edu.
Abstract
OBJECTIVES: Findings from a brief geriatric assessment (GA) in a cohort of adults with multiple myeloma (MM) are presented, with particular attention to the utility of the GA in identifying important deficits in adults judged to have a normal Karnofsky Performance Status (KPS ≥ 80). MATERIALS AND METHODS: Adults age 18 and older with MM were recruited into an observational study from 2018 to 2020. A modified Cancer and Aging Research Group (CARG) GA was administered at enrollment. Enrollees also completed the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life of Cancer Patients Core 30 questionnaire (QLQ-C30), with subscales of physical, social, role, and cognitive functioning (range 0-100; higher values indicate better function). Data were analyzed using descriptive statistics for the full cohort and stratified by concurrent KPS (score < 80 vs ≥ 80). RESULTS: Among 89 adults, the mean age was 69.1 years, 68% were aged ≥65 years, and 70% were white. In this cohort, 78% had KPS ≥ 80. Among those with KPS ≥ 80, functional impairments (Timed Up and Go ≥14 s and dependence in ≥1 instrumental activity of daily living) were seen in 30% and 21%, respectively, with 11% reporting ≥1 fall in the prior 6 months. At least two GA-identified deficits were detected in 50% of the overall cohort and in 41% of those with KPS ≥ 80. Among those with KPS ≥ 80, self-reported physical impairment on EORTC QLQ-C30 was noted by 34%. CONCLUSION: Using a modified CARG GA and EORTC questionnaire, functional impairments were identified among adults considered to have a good performance status based on a KPS (≥ 80). Future studies should focus on using GA measures for therapy assignment and identifying opportunities for intervening upon GA-identified deficits.
OBJECTIVES: Findings from a brief geriatric assessment (GA) in a cohort of adults with multiple myeloma (MM) are presented, with particular attention to the utility of the GA in identifying important deficits in adults judged to have a normal Karnofsky Performance Status (KPS ≥ 80). MATERIALS AND METHODS: Adults age 18 and older with MM were recruited into an observational study from 2018 to 2020. A modified Cancer and Aging Research Group (CARG) GA was administered at enrollment. Enrollees also completed the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life of Cancer Patients Core 30 questionnaire (QLQ-C30), with subscales of physical, social, role, and cognitive functioning (range 0-100; higher values indicate better function). Data were analyzed using descriptive statistics for the full cohort and stratified by concurrent KPS (score < 80 vs ≥ 80). RESULTS: Among 89 adults, the mean age was 69.1 years, 68% were aged ≥65 years, and 70% were white. In this cohort, 78% had KPS ≥ 80. Among those with KPS ≥ 80, functional impairments (Timed Up and Go ≥14 s and dependence in ≥1 instrumental activity of daily living) were seen in 30% and 21%, respectively, with 11% reporting ≥1 fall in the prior 6 months. At least two GA-identified deficits were detected in 50% of the overall cohort and in 41% of those with KPS ≥ 80. Among those with KPS ≥ 80, self-reported physical impairment on EORTC QLQ-C30 was noted by 34%. CONCLUSION: Using a modified CARG GA and EORTC questionnaire, functional impairments were identified among adults considered to have a good performance status based on a KPS (≥ 80). Future studies should focus on using GA measures for therapy assignment and identifying opportunities for intervening upon GA-identified deficits.
Authors: Johannes M Giesinger; Fanny L C Loth; Neil K Aaronson; Juan I Arraras; Giovanni Caocci; Fabio Efficace; Mogens Groenvold; Marieke van Leeuwen; Morten Aa Petersen; John Ramage; Krzysztof A Tomaszewski; Teresa Young; Bernhard Holzner Journal: J Clin Epidemiol Date: 2019-10-19 Impact factor: 6.437
Authors: Ashley E Rosko; Ying Huang; Don M Benson; Yvonne A Efebera; Craig Hofmeister; Samantha Jaglowski; Steven Devine; Geetika Bhatt; Tanya M Wildes; Alanna Dyko; Desirée Jones; Michelle J Naughton; John C Byrd; Christin E Burd Journal: J Geriatr Oncol Date: 2018-07-06 Impact factor: 3.599
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Christopher E Jensen; Sanah N Vohra; Kirsten A Nyrop; Allison M Deal; Matthew R LeBlanc; Shakira J Grant; Hyman B Muss; Eben I Lichtman; Samuel M Rubinstein; William A Wood; Nicholas J Mangieri; Lee Jamison; Sascha A Tuchman Journal: Oncologist Date: 2022-08-05 Impact factor: 5.837